Quidel Corporation (Nasdaq: QDEL) is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel's core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Its current products fall generally into these categories:
- Lateral flow, where they are market leaders in infectious disease and reproductive health.
- Direct fluorescent antibodies (DFA), with expertise in infectious disease and virology.
- Micro-titer production, with a focus on bone and complement pathway markets.
- Fluorescent immunoassay products (Sofia)
- Molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue.
